Official announcements
Search narrowed by
Medicines
|
19/11/2013
The company responsible for distribution, sigma-tau ArzneimittelGmbH, 40212 Düsseldorf, Germany, informed its supplied customers on November 15, 2013, that individual containers of the above-mentioned batches may have fine cracks that may lead to…
Recall
|
Medicines
|
12/11/2013
Due to a possible quality defect, the companies Sigma-Tau Arzneimittel GmbH and Sigma-Tau Rare Diseases S.A. have decided to recall the above mentioned batches of Oncaspar® Injection Solution.Both companies have been informed by the manufacturer of…
Recall
|
Medicines
|
11/11/2013
Due to a technical defect, there is a possibility in a small number of Jext epinephrine auto-injectors that the epinephrine is not correctly applied to the muscle when the auto-injector is triggered.
Recall
|
Medicines
|
08/11/2013
In a small number (0.04% corresponds to 4/10,000) of Jext® pre-filled pens, the adrenaline injection may not be carried out in case of need due to a technical defect. The affected batches will therefore be replaced immediately. To ensure immediate…
Replacement
|
Medicines
|
25/10/2013
Due to a manufacturing problem during the filling of the cartridges, individual products of the above mentioned batches of "NovoMix® 30 FLexPen®" may have an insulin content that is too high or too low. According to information from the Danish…
Recall
|
Medicines
|
14/10/2013
The marketing authorization holder has informed its supplied customers in a letter dated 11.10.2013 that complaints have arisen describing the disintegration of the pen after repeated use. Since the pen can no longer be used after this, a…
Recall
|
Medicines
|
09/10/2013
On October 8, 2013, the marketing authorization holder informed its customers that injection vials may have an externally invisible defect under the crimp cap due to the capping machine and that product leakage may occur when the vial is shaken.…
Replacement
|
Medicines
|
02/10/2013
During a routine quality check, a small number of prefilled syringes were found to contain particles consisting mainly of cellulose fibers. The voluntary exchange only affects investigational products with the above batch numbers that were marketed…
Recall
|
Medicines
|
17/09/2013
The marketing authorization holder has informed its supplied customers in a letter dated 13.09.2013 that investigations have shown that the optimal efficacy of batch 15159721 cannot be guaranteed over the entire shelf life and therefore a…
Replacement
|
Medicines
|
22/08/2013
The marketing authorization holder informed its supplied customers in a letter dated August 22, 2013, that visible particles were detected in some vials and that a recall of the two affected batches will therefore be carried out.